{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:03:18Z","timestamp":1790506998913,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T00:00:00Z","timestamp":1317945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2407-11-432","type":"journal-article","created":{"date-parts":[[2011,10,7]],"date-time":"2011-10-07T17:40:03Z","timestamp":1318009203000},"source":"Crossref","is-referenced-by-count":64,"title":["A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients"],"prefix":"10.1186","volume":"11","author":[{"given":"Mark J","family":"McKeage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Amies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa J","family":"Melink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,7]]},"reference":[{"issue":"13","key":"2926_CR1","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","volume":"13","author":"AV Patterson","year":"2007","unstructured":"Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al: Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007, 13 (13): 3922-3932. 10.1158\/1078-0432.CCR-07-0478.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2926_CR2","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-08-4023","volume":"69","author":"RS Singleton","year":"2009","unstructured":"Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR: DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity. Cancer Res. 2009, 69 (9): 3884-3891. 10.1158\/0008-5472.CAN-08-4023.","journal-title":"Cancer Res"},{"issue":"4","key":"2926_CR3","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","volume":"70","author":"CP Guise","year":"2010","unstructured":"Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al: The Bioreductive Prodrug PR-104A is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3. Cancer Res. 2010, 70 (4): 1573-1584. 10.1158\/0008-5472.CAN-09-3237.","journal-title":"Cancer Res"},{"issue":"6","key":"2926_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.bcp.2007.06.014","volume":"74","author":"CP Guise","year":"2007","unstructured":"Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, Patterson AV: Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: A role for NADPH: cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol. 2007, 74 (6): 810-820. 10.1016\/j.bcp.2007.06.014.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"2926_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1158\/1535-7163.MCT-08-1209","volume":"8","author":"Y Gu","year":"2009","unstructured":"Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, Wilson WR: Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009, 8 (6): 1714-1723. 10.1158\/1535-7163.MCT-08-1209.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2926_CR6","first-page":"1408","volume":"58","author":"JM Brown","year":"1998","unstructured":"Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58 (7): 1408-1416.","journal-title":"Cancer Res"},{"issue":"2","key":"2926_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0959-8049(01)00361-6","volume":"38","author":"BG Wouters","year":"2002","unstructured":"Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P: Hypoxia as a target for combined modality treatments. Eur J Cancer. 2002, 38 (2): 240-257. 10.1016\/S0959-8049(01)00361-6.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2926_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004, 4 (6): 437-447. 10.1038\/nrc1367.","journal-title":"Nat Rev Cancer"},{"issue":"1-2","key":"2926_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.mce.2005.11.038","volume":"248","author":"K Ito","year":"2006","unstructured":"Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira JI, Okamura K, Yaegashi N, Sasano H: 17 beta-hydroxy steroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol. 2006, 248 (1-2): 136-140. 10.1016\/j.mce.2005.11.038.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2926_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/jcp.2007.050906","volume":"61","author":"K Wako","year":"2008","unstructured":"Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, et al: Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol. 2008, 61 (4): 448-454. 10.1136\/jcp.2007.050906.","journal-title":"J Clin Pathol"},{"issue":"1","key":"2926_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bbrc.2005.08.194","volume":"338","author":"M Sakurai","year":"2005","unstructured":"Sakurai M, Oishi K, Watanabe K: Localization of cyclooxygenases-1 and-2, and prostaglandin F synthase in human kidney and renal cell carcinoma. Biochem Biophys Res Commun. 2005, 338 (1): 82-86. 10.1016\/j.bbrc.2005.08.194.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2926_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ijrobp.2007.05.049","volume":"69","author":"KO Hicks","year":"2007","unstructured":"Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR: Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys. 2007, 69 (2): 560-571. 10.1016\/j.ijrobp.2007.05.049.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2926_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00280-010-1412-z","volume":"67","author":"K Patel","year":"2011","unstructured":"Patel K, Choy SSF, Hicks KO, Melink TJ, Holford NH, Wilson WR: A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol. 2011, 67 (5): 1145-1155. 10.1007\/s00280-010-1412-z.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2926_CR14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00280-009-1188-1","volume":"65","author":"MB Jameson","year":"2010","unstructured":"Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR: A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010, 65 (4): 791-801. 10.1007\/s00280-009-1188-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2926_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1124\/dmd.109.030973","volume":"38","author":"Y Gu","year":"2010","unstructured":"Gu Y, Atwell GJ, Wilson WR: Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans. Drug Metab Dispos. 2010, 38 (3): 498-508. 10.1124\/dmd.109.030973.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"2926_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.111.180703","volume":"337","author":"Y Gu","year":"2011","unstructured":"Gu Y, Tingle MD, Wilson WR: Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy. J Pharmacol Exp Ther. 2011, 337 (3): 692-702. 10.1124\/jpet.111.180703.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2926_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid Tumors. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"2926_CR18","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1016\/j.jchromb.2009.08.009","volume":"877","author":"Y Gu","year":"2009","unstructured":"Gu Y, Wilson WR: Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877 (27): 3181-3186. 10.1016\/j.jchromb.2009.08.009.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1-2","key":"2926_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jlcr.1147","volume":"50","author":"GJ Atwell","year":"2007","unstructured":"Atwell GJ, Denny WA: Synthesis of H-3- and H-2(4)-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)carbonyl) anilino)ethyl methanesulfonate (PR-104). J Label Compd Radiopharm. 2007, 50 (1-2): 7-12.","journal-title":"J Label Compd Radiopharm"},{"issue":"3","key":"2926_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00280-010-1354-5","volume":"67","author":"Y Gu","year":"2011","unstructured":"Gu Y, Guise CP, Patel K, Abbattista MR, Lie J, Sun X, Atwell GJ, Boyd M, Patterson AV, Wilson WR: Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol. 2011, 67 (3): 543-555. 10.1007\/s00280-010-1354-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2926_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","volume":"60","author":"K Bowalgaha","year":"2005","unstructured":"Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO: S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005, 60 (4): 423-433. 10.1111\/j.1365-2125.2005.02446.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1-2","key":"2926_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mrfmmm.2008.12.010","volume":"662","author":"J Birtwistle","year":"2009","unstructured":"Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, et al: The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res. 2009, 662 (1-2): 67-74.","journal-title":"Mutat Res"},{"issue":"13","key":"2926_CR23","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1073\/pnas.0701152104","volume":"104","author":"K Parmar","year":"2007","unstructured":"Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD: Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA. 2007, 104 (13): 5431-5436. 10.1073\/pnas.0701152104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2926_CR24","doi-asserted-by":"publisher","first-page":"e23108","DOI":"10.1371\/journal.pone.0023108","volume":"6","author":"J Benito","year":"2011","unstructured":"Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, et al: Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS One. 2011, 6 (8): e23108-10.1371\/journal.pone.0023108.","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-432\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T16:16:39Z","timestamp":1468340199000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2926"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-432","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,7]]},"article-number":"432"}}